Benidipine(105979-17-7)C28H31N3O6

Description

What is Benidipine?

Benidipine has the formula 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester hydrochloride. It is a synthetic dihydropyridine derivative that has anti-hypertensive and anti-anginal actions. It was originated in Japan by Kyowa Hakko, it is submitted for FDA approval and it is currently available in some Asian countries like India and Japan.

Basic information

Product Name:	Benidipine
Synonyms:	Benidipene; Benidipine INN; Benidipino; Benidipinum; Benidipino
CAS:	105979-17-7
MF:	C28H31N3O6
MW:	505.56
Product Categories:	API; Intermediates & Fine Chemicals; Pharmaceuticals

Chemical Structure

Benidipine

Chemical Properties

Boiling point	625.2±55.0 °C(Predicted)
density	1.29±0.1 g/cm3(Predicted)
pka	pKa 7.34(H2O(long extrapolation) ) (Uncertain)

Benidipine Uses And Synthesis

1 Antihypertensive effect

Oral administration of this product to spontaneously hypertensive rats, DOCA-salt hypertensive rats, and renal hypertensive dogs, showing a slow and continuous antihypertensive effect. Long-term administration does not produce drug resistance. When patients with essential hypertension orally take this product once a day, it does not affect the intra-day changes in blood pressure and shows a stable blood pressure lowering effect within 24 hours.

2 Anti-angina pectoris effect

This agent has a significant improvement effect on experimental angina pectoris model (rat) and dog coronary artery ligation and reperfusion caused by low heart function and ischemic ECG changes. When taking this product orally to patients with exertional angina pectoris, it shows that this product can improve the ischemic changes caused by exercise load (decrease in ST segment of electrocardiogram).

3 Protecting renal function

When continuous oral administration of this product to spontaneously hypertensive rats with renal insufficiency (nephrectomy 5/6), it can improve renal function while showing the effect of lowering blood pressure. Patients with essential hypertension can see a significant increase in renal blood flow when oral administration of this product. After oral administration of this product in patients with hypertension and chronic renal insufficiency, the creatinine clearance rate and the clearance rate of urea nitrogen increased significantly, showing the protective effect of renal function.

4 Inhibit vascular remodeling and protect vascular endothelium.

This product increases NO production by activating endothelial NO synthase (eNOS) and enhancing eNOS gene expression, and inhibits NO inactivation through its antioxidant effect, and ultimately expands NO biological activity. Thereby inhibiting vascular remodeling and protecting the vascular endothelium.

Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

MSDS: MSDS available.

COA: COA can be available if you send us inquiry.

Email us at: info@maxmedchem.com for more details.